News & Updates

Original New Drug Application Approvals by US FDA (1-15 March 2025)

04 Apr 2025

New drug applications approved by US FDA as of 1-15 March 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 March 2025)

04 Apr 2025

Sjögren disease patients at increased risk of death

25 Mar 2025

Patients with Sjögren disease (SD) are at heightened risk of mortality from infections, malignancies, and cardiovascular disease (CVD), reveals a study.

Sjögren disease patients at increased risk of death

25 Mar 2025

Low creatinine-cystatin C ratio a red flag for muscle volume, gait speed

24 Mar 2025

Among middle-aged women, low creatinine-cystatin C ratio is predictive of reduced fat-free muscle volumes and poorer gait speeds after more than 6 years, as shown in a study.

Low creatinine-cystatin C ratio a red flag for muscle volume, gait speed

24 Mar 2025

Anxiety, depression prevalent in people with RA

24 Mar 2025

Individuals with rheumatoid arthritis (RA) are at an increased risk of developing anxiety or both depression and anxiety, according to a study.

Anxiety, depression prevalent in people with RA

24 Mar 2025

4 in 10 adults with chronic pain face mental health woes

18 Mar 2025 by

Chronic pain is accompanied by depression and anxiety in 40 percent of adults, according to the results of a meta-analysis.

4 in 10 adults with chronic pain face mental health woes

18 Mar 2025

$Abaloparatide helps prevent fractures in most vulnerable postmenopausal women$

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

17 Mar 2025 by

Treatment with abaloparatide appears to reduce the incidence of fractures as well as improve bone mineral density (BMD) in the subgroup of postmenopausal women at highest risk of fracture, according to a post hoc analysis of the ACTIVE* study.

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

17 Mar 2025

Wearable device improves fatigue, life quality in SSc patients

15 Mar 2025 by

Use of the Apollo wearable for 1 month leads to improvements in fatigue and Raynaud phenomenon (RP) symptoms in patients with systemic sclerosis (SSc), according to a pilot study.

Wearable device improves fatigue, life quality in SSc patients

15 Mar 2025

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025 by

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Original New Drug Application Approvals by US FDA (1-15 March 2025)

Original New Drug Application Approvals by US FDA (1-15 March 2025)

Sjögren disease patients at increased risk of death

Sjögren disease patients at increased risk of death

Low creatinine-cystatin C ratio a red flag for muscle volume, gait speed

Low creatinine-cystatin C ratio a red flag for muscle volume, gait speed

Anxiety, depression prevalent in people with RA

Anxiety, depression prevalent in people with RA

4 in 10 adults with chronic pain face mental health woes

4 in 10 adults with chronic pain face mental health woes

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

Abaloparatide helps prevent fractures in most vulnerable postmenopausal women

Wearable device improves fatigue, life quality in SSc patients

Wearable device improves fatigue, life quality in SSc patients

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab